We are live on
!
Find out more
SCM
Sio Capital Management Portfolio holdings
AUM
$604M
1-Year Est. Return
96.57%
This Fund
S&P 500
This Quarter
Est. Return
+11.78%
1 Year Est. Return
+96.57%
3 Year Est. Return
+564.25%
5 Year Est. Return
+486.18%
10 Year Est. Return
+2,856.71%
AUM
$291M
AUM Growth
+$111M
(+61%)
Cap. Flow
+$63.6M
Cap. Flow
% of AUM
21.82%
Top 10 Holdings %
Top 10 Hldgs %
41.32%
Holding
85
New
36
Increased
17
Reduced
10
Closed
22
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
GSK
GSK
|
+$14.8M |
| 2 |
Bionano Genomics
BNGO
|
+$10.2M |
| 3 |
Alnylam Pharmaceuticals
ALNY
|
+$7.48M |
| 4 |
UROV
Urovant Sciences Ltd.
UROV
|
+$6.99M |
| 5 |
Biogen
BIIB
|
+$6.64M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Boston Scientific
BSX
|
+$5.97M |
| 2 |
Elevance Health
ELV
|
+$4.88M |
| 3 |
Icon
ICLR
|
+$4.61M |
| 4 |
Willis Towers Watson
WTW
|
+$3.94M |
| 5 |
Revvity
RVTY
|
+$3.85M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 76.22% |
| 2 | Miscellaneous | 19.57% |
| 3 | Financials | 4.21% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
GSK
GSK
$102B
| $14.6M | 5.02% |
+291,168
| New | +$14.8M |
|
2
Cigna
CI
$73.7B
| $14M | 4.82% |
67,449
+28,249
| +72% | +$5.24M |
|
3
PUT
Pacira BioSciences
PCRX
$1.03B
| $13.8M | 4.74% |
+281,100
| New | +$12.2M |
|
4
Kura Oncology
KURA
$1.13B
| $12.7M | 4.37% |
727,258
-110,346
| -13% | -$2.12M |
|
|
AET
5
DELISTED
Aetna Inc
AET
| $12.3M | 4.21% |
60,444
+21,309
| +54% | +$4.16M |
|
6
Sanofi
SNY
$107B
| $11.9M | 4.08% |
266,388
+116,330
| +78% | +$4.97M |
|
7
HCA Healthcare
HCA
$90.5B
| $11.7M | 4% |
83,822
-13,408
| -14% | -$1.67M |
|
8
PUT
Amgen
AMGN
$234B
| $10.4M | 3.56% |
+50,000
| New | +$9.85M |
|
|
LITS
9
Lite Strategy Inc
LITS
$33.4M
| $9.93M | 3.41% |
115,182
+5,983
| +5% | +$490K |
|
|
10
Alnylam Pharmaceuticals
ALNY
$31.7B
| $9.12M | 3.13% |
104,176
+74,341
| +249% | +$7.48M |
|
|
11
Bionano Genomics
BNGO
$13.8M
| $7.35M | 2.52% |
+2,401
| New | +$10.2M |
|
|
UROV
12
DELISTED
Urovant Sciences Ltd.
UROV
| $7.1M | 2.44% |
+591,454
| New | +$6.99M |
|
|
13
Biogen
BIIB
$32.3B
| $6.82M | 2.34% |
+19,300
| New | +$6.64M |
|
|
14
Elevance Health
ELV
$85.5B
| $6.8M | 2.33% |
24,803
-18,798
| -43% | -$4.88M |
|
15
Humana
HUM
$46.3B
| $6.79M | 2.33% |
20,054
+2,261
| +13% | +$735K |
|
|
PINC
16
DELISTED
Premier
PINC
| $6.61M | 2.27% |
+144,412
| New | +$5.83M |
|
17
PUT
Dentsply Sirona
XRAY
$2.22B
| $6.42M | 2.2% |
+170,000
| New | +$7.08M |
|
18
CALL
Merck
MRK
$366B
| $5.96M | 2.04% |
+88,032
| New | +$5.61M |
|
19
Gyre Therapeutics
GYRE
$699M
| $5.94M | 2.04% |
73,464
+10,604
| +17% | +$840K |
|
20
Rigel Pharmaceuticals
RIGL
$868M
| $5.92M | 2.03% |
184,350
+44,488
| +32% | +$1.34M |
|
21
Universal Health Services
UHS
$10.1B
| $5.29M | 1.82% |
41,393
+6,070
| +17% | +$745K |
|
22
Smith & Nephew
SNN
$12.1B
| $4.98M | 1.71% |
+134,388
| New | +$4.85M |
|
23
Novartis
NVS
$292B
| $4.97M | 1.71% |
64,383
+3,003
| +5% | +$222K |
|
|
AMAG
24
PUT
DELISTED
AMAG Pharmaceuticals
AMAG
| $4.52M | 1.55% |
+226,200
| New | +$5.15M |
|
|
FOMX
25
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
| $4.41M | 1.51% |
+770,000
| New | +$4.4M |
|
Similar funds
EFL
V
MAM
RCM
AMG
VV
VCP
EHI
Sio Capital Management's Q3 2018 Portfolio in Review
As of Q3 2018, Sio Capital Management held 85 positions worth $291M, up 61% from $181M the previous quarter. Its ten largest holdings account for 41% of the portfolio.
Sio Capital Management deployed $63.6M of net new capital in Q3 2018, opening 36 new positions and adding to 17 existing holdings. Its largest new stake was GSK: 291,168 shares worth $14.6M.
By sector, the portfolio is most concentrated in Healthcare at 76% of assets, down from 83% a quarter earlier, followed by Miscellaneous and Financials.
On the sell side, the largest reduction was Elevance Health, an estimated $4.88M trimmed.
- Sio Capital Management's largest Q3 2018 buy was GSK: 291,168 shares worth $14.6M.
- Sio Capital Management added most to Alnylam Pharmaceuticals in Q3 2018, an estimated $7.48M increase.
- Sio Capital Management's biggest Q3 2018 reduction was Elevance Health, cutting an estimated $4.88M.
- Sio Capital Management fully exited Boston Scientific in Q3 2018, selling an estimated $5.97M.
- Sio Capital Management's ten largest holdings make up 41% of its $291M portfolio in Q3 2018.
- Sio Capital Management opened 36 new positions and closed 22 in Q3 2018.
- Sio Capital Management's portfolio value rose 61% quarter-over-quarter to $291M.
Based on Sio Capital Management's 13F filing for Q3 2018, filed 14 Nov 2018.